The following words and terms, when used in this chapter, shall
have the following meanings, unless the context clearly indicates
otherwise.
(1) Advisory Committee--a committee of experts, including
practitioners and patient advocates, created by the Oversight Committee
to advise the Oversight Committee on issues related to cancer.
(2) Allowable Cost--a cost that is reasonable, necessary
for the proper and efficient performance and administration of the
project, and allocable to the project.
(3) Annual Public Report--the report issued by the
Institute pursuant to Texas Health and Safety Code §102.052 outlining
Institute activities, including Grant Awards, research accomplishments,
future Program directions, compliance, and Conflicts of Interest actions.
(4) Approved Budget--the financial expenditure plan
for the Grant Award, including revisions approved by the Institute
and permissible revisions made by the Grant Recipient. The Approved
Budget may be shown by Project Year and detailed budget categories.
(5) Authorized Expense--cost items including honoraria,
salaries and benefits, consumable supplies, other operating expenses,
contracted research and development, capital equipment, construction
or renovation of state or private facilities, travel, and conference
fees and expenses.
(6) Authorized Signing Official (ASO)--the individual,
including designated alternates, named by the Grant Applicant, who
is authorized to act for the Grant Applicant or Grant Recipient in
submitting the Grant Application and executing the Grant Contract
and associated documents or requests.
(7) Bylaws--the rules established by the Oversight
Committee to provide a framework for its operation, management, and
governance.
(8) Cancer Prevention--a reduction in the risk of developing
cancer, including early detection, control and/or mitigation of the
incidence, disability, mortality, or post-diagnosis effects of cancer.
(9) Cancer Prevention and Control Program--effective
strategies and interventions for preventing and controlling cancer
designed to reduce the incidence and mortality of cancer and to enhance
the quality of life of those affected by cancer.
(10) Cancer Prevention and Research Fund--the dedicated
account in the general revenue fund consisting of legislative appropriations,
gifts, grants, other donations, and earned interest.
(11) Cancer Research--research into the prevention,
causes, detection, treatments, and cures for all types of cancer in
humans, including basic mechanistic studies, pre-clinical studies,
animal model studies, translational research, and clinical research
to develop preventative measures, therapies, protocols, medical pharmaceuticals,
medical devices or procedures for the detection, treatment, cure or
substantial mitigation of all types of cancer and its effects in humans.
(12) Chief Compliance Officer--the individual employed
by the Institute to monitor and report to the Oversight Committee
regarding compliance with the Institute's statute and administrative
rules. The term may also apply to an individual designated by the
Chief Compliance Officer to fulfill the duty or duties described herein,
unless the context clearly indicates otherwise.
(13) Chief Executive Officer--the individual hired
by the Oversight Committee to perform duties required by the Institute's
Statute or designated by the Oversight Committee. The term may apply
to an individual designated by the Chief Executive Officer to fulfill
the duty or duties described herein, unless the context clearly indicates
otherwise.
(14) Chief Prevention Officer--the individual hired
by the Chief Executive Officer to oversee the Institute's Cancer Prevention
program, including the Grant Review Process, and to assist the Chief
Executive Officer in collaborative outreach to further Cancer Research
and Cancer Prevention. The term may also apply to an individual designated
by the Chief Prevention Officer to fulfill the duty or duties described
herein, unless the context clearly indicates otherwise.
(15) Chief Product Development Officer--the individual
hired by Chief Executive Officer to oversee the Institute's Product
Development program for drugs, biologicals, diagnostics, or devices
arising from Cancer Research, including the Grant Review Process,
and to assist the Chief Executive Officer in collaborative outreach
to further Cancer Research and Cancer Prevention. The term may apply
to an individual designated by the Chief Product Development Officer
to fulfill the duty or duties described herein, unless the context
clearly indicates otherwise.
(16) Chief Scientific Officer--the individual hired
by the Chief Executive Officer to oversee the Institute's Cancer Research
program, including the Grant Review Process, and to assist the Chief
Executive Officer in collaborative outreach to further Cancer Research
and Cancer Prevention. The term may apply to an individual designated
by the Chief Scientific Officer to fulfill the duty or duties described
herein, unless the context clearly indicates otherwise.
(17) Code of Conduct and Ethics--the code adopted by
the Oversight Committee pursuant to Texas Health and Safety Code §102.109
to provide guidance related to the ethical conduct expected of Oversight
Committee Members, Program Integration Committee Members, and Institute
Employees.
(18) Compliance Program--a process to assess and ensure
compliance by the Oversight Committee Members and Institute Employees
with applicable laws, rules, and policies, including matters of ethics
and standards of conduct, financial reporting, internal accounting
controls, and auditing.
(19) Conflict(s) of Interest--a financial, professional,
or personal interest held by the individual or the individual's Relative
that is contrary to the individual's obligation and duty to act for
the benefit of the Institute.
(20) Encumbered Funds--funds that are designated by
a Grant Recipient for a specific purpose.
(21) Financial Status Report--form used to report all
Grant Award related financial expenditures incurred in implementation
of the Grant Award. This form may also be referred to as "FSR" or
"Form 269-A."
(22) Grant Applicant--the public or private institution
of higher education, as defined by §61.003, Texas Education Code,
research institution, government organization, non-governmental organization,
non-profit organization, other public entity, private company, individual,
or consortia, including any combination of the aforementioned, that
submits a Grant Application to the Institute. Unless otherwise indicated,
this term includes the Principal Investigator or Program Director.
(23) Grant Application--the written proposal submitted
by a Grant Applicant to the Institute in the form required by the
Institute that, if successful, will result in a Grant Award.
(24) Grant Award--funding, including a direct company
investment, awarded by the Institute pursuant to a Grant Contract
providing money to the Grant Recipient to carry out the Cancer Research
or Cancer Prevention project in accordance with rules, regulations,
and guidance provided by the Institute.
(25) Grant Contract--the legal agreement executed by
the Grant Recipient and the Institute setting forth the terms and
conditions for the Cancer Research or Cancer Prevention Grant Award
approved by the Oversight Committee.
(26) Grant Management System--the electronic interactive
system used by the Institute to exchange, record, and store Grant
Application and Grant Award information.
(27) Grant Mechanism--the specific Grant Award type.
(28) Grant Program--the functional area in which the
Institute makes Grant Awards, including research, prevention and product
development.
(29) Grant Progress Report--the required report submitted
by the Grant Recipient at least annually and at the close of the grant
award describing the activities undertaken to achieve the Scope of
Work of the funded project and including information, data and program
metrics. Unless the context clearly indicates otherwise, the Grant
Progress Report also includes other required reports such as a Historically
Underutilized Business and Texas Supplier form, a single audit determination
form, an inventory report, a single audit determination form, a revenue
sharing form, and any other reports or forms designated by the Institute.
(30) Grant Recipient--the entire legal entity responsible
for the performance or administration of the Grant Award pursuant
to the Grant Contract. Unless otherwise indicated, this term includes
the Principal Investigator, Program Director, or Company Representative.
(31) Grant Review Cycle--the period that begins on
the day that the Request for Applications is released for a particular
Grant Mechanism and ends on the day that the Oversight Committee takes
action on the Grant Award recommendations.
(32) Grant Review Process--the Institute's processes
for Peer Review, Program Review and Oversight Committee approval of
Grant Applications.
Cont'd... |
